Researcher Spotlight: Michelle Lee, MD, PhD emory university Black patients with diffuse large B-cell lymphoma (DLBCL) tend to have worse outcomes than patients from other groups. These differences may be due to a combination of biological and genetic factors, but…
Researcher Spotlight: Kazuya Fukasawa, PhD memorial sloan kettering cancer center Condon Family Fellow The introduction of bispecific antibodies represents a promising therapeutic advancement in the treatment of lymphoma. These therapies work by redirecting T-cells to interact with tumor cells, supporting…
Researcher Spotlight: Pantaleo De Simone, MD columbia university irving medical center Diffuse large B-cell lymphoma (DLBCL) is an aggressive and often incurable form of lymphoma. An improved understanding of DLBCL biology is needed to identify potential treatment strategies, and Dr.…
Researcher Spotlight: Robert Stuver, MD memorial sloan kettering cancer center Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is an aggressive T-cell lymphoma that primarily occurs in young adults. Many patients can be cured with chemotherapy, but if the…
Researcher Spotlight: Paola Ghione, MD memorial sloan kettering cancer center Skin infections and bacterial colonization are known to play an important role in the development and severity of cutaneous T-cell lymphomas (CTCLs). Topical treatments, including bleach baths and antiseptic creams,…
Researcher Spotlight: Jordan Goldstein, MD Leland stanford Junior University Despite effective options for first-line treatment, many people with diffuse large B-cell lymphoma (DLBCL) still experience relapse. Novel chimeric antigen receptor (CAR) T-cell therapies are often used after relapse in DLBCL,…
Researcher Spotlight: Robert Albero Gallego, PhD COLUMBIA UNIVERSITY Angioimmunoblastic T-cell lymphomas (AITLs) are aggressive forms of blood cancer and are often resistant to conventional chemotherapy. Certain mutations have been to be very common in AITLs, including mutations in the TET2…
Researcher Spotlight: Preteesh Jain, MD, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Chemotherapy-sparing treatment regimens are of great interest for many patients with lymphoma due to the variety of short- and long-term toxicities associated with These therapies. To this…
Researcher Spotlight: Haopeng Yang, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Super-enhancers are regions of the genome responsible for regulating expression of an unusually high number of genes. For his Lymphoma Research Foundation-funded project, Dr. Yang is characterizing the…
Researcher Spotlight: Min Xia, PhD WEILL CORNELL MEDICINE Among the different subtypes of diffuse large B-cell lymphoma (DLBCL), ABC-DLBCL represents one of the most aggressive forms with low response rates to standard chemotherapeutic approaches. Improved treatment approaches in this space…
